



Volume 13, Issue 3
May 2015 – July 2015

Pharmacy Benefits Management- Medical Advisory Panel- VISN Pharmacist Executives E_z - MINUTES

Watch for the next issue of Ez-Minutes Tuesday, November 3rd, 2015
See us at: <http://www.pbm.va.gov/> or <https://vaww.cmopnational.va.gov/cmop/PBM/default.aspx>.

[Click Here to Subscribe to the Ez Minutes](#)

The purpose of PBM-MAP-VPE Ez-Minutes Newsletter is to communicate with the field on items which will impact clinical practice in the VA. Please send and feedback and/or comments to Janet.Dailey@VA.gov.

Posting of National PBM Documents May – July 2015

Formulary Decisions

ADDED to the VA National Formulary (VANF)	NOT ADDED to the National Formulary (VANF)	Removed from the National Formulary (VANF)
<ul style="list-style-type: none"> Abacavir/dolutegravir/lamivudine Amphetamine + dexamphetamine, mixed amphetamine salts IR and SA forms (ADDERALL) Ciprofloxacin and dexamethasone Otic Suspension Darunavir/cobicistat Doxylamine [Restricted to women's health] Phenylephrine Tbo-filgrastim 	<ul style="list-style-type: none"> Albendazole Chewable Tabs Apremilast [See CFU] Atazanavir/cobicistat Budesonide ER Tab [See CFU] C1 Esterase Inhibitor (recombinant) Cabozantinib Cholic Acid [Capsules, Oral] Cobicistat Dalbavancin Elvitegravir Fluticasone furoate Idelalisib [See CFU] Inhaled Insulin [See CFU] Ivermectin 1% Cream [See CFU] Lenvatinib Memantine ER + donepezil Metreleptin Naloxegol Omalizumab [See CFU] Oritavancin Phenylephrine/Ketorolac Ophthalmic Injection Ramucirumab [See CFU] Sorafenib [In Differentiated Thyroid Carcinoma] Sotalol Oral Solution Umeclidinium Ellipta Vandetanib 	<ul style="list-style-type: none"> Chloral Hydrate (capsule and syrup-no longer marketed) Mebendazole (no longer marketed) Ofloxacin Otic Solution Thiabendazole (no longer marketed)
Drug Monograph		
<ul style="list-style-type: none"> Apremilast C1 Inhibitor Collagenase Clostridium Histolyticum [Updated July 2015] Dalbavancin Inhaled Insulin Icatibant Monograph Addendum [data on angiotensin-converting enzyme inhibitor-induced angioedema (off-label use)] Icatibant [revised shelf life info only] Ivermectin 1% Cream Naloxegol [Updated July 2015] Oritavancin Phenylephrine/Ketorolac Ophthalmic Injection Ramucirumab [Updated June 2015] Sorafenib [In Differentiated Thyroid Carcinoma] Tbo-filgrastim 		
Criteria for Use (CFU)		
<ul style="list-style-type: none"> Apremilast [In Psoriasis and Psoriatic Arthritis] Budesonide ER Tab C1 (Esterase) Inhibitor (recombinant) [Ecallantide, Icatibant for Hereditary Angioedema, Updated June 2015] Fingolimod [Updated June 2015] Idelalisib Inhaled Insulin Ivermectin 1% Cream Naloxegol Omalizumab [In Chronic Idiopathic or Spontaneous Urticaria] Ramucirumab Teriflunomide [Updated June 2015] 	Other Helpful Resources	
Abbreviated Review		
<ul style="list-style-type: none"> Integrase Inhibitor-based regimens: Abacavir/dolutegravir/lamivudine and Elvitegravir Cabozantinib Cobicistat Elvitegravir Fluticasone furoate HIV Protease-Inhibitors-based regimens: Darunavir/cobicistat, Atazanavir/cobicistat and Cobicistat Lenvatinib Umeclidinium Ellipta Vandetanib 	<ul style="list-style-type: none"> Determining Clinical Benefit of High Cost Oncology Drugs National Contract Awards CY2015 Sotalol Patient Information [Updated July 2015] Sotalol Provider Information [Updated July 2015] 	
Clinical Recommendations		
<ul style="list-style-type: none"> Gram-Positive Recs for Use for Newer MRSA Agents [Updated June 2015] Naloxone Kits and Autoinjector [Updated June 2015] 		

Inside This Issue

[Posting of National PBM Documents](#) May-July 2015

[Posting of VAMedSAFE Documents](#) May- July 2015

[VHA Oncology Documents](#)

[Pharmacy-Prosthetics-Logistics and Acquisitions \(PPL\) Workgroup](#) May-July 2015

[National Contract Awards for CY 2015](#)

[PBM-MAP-VPE Webinars](#)

Aug. 18th: Clinical Pharmacy Handbook

Sept. 15th: VA-DoD Lipid Guidelines

[Anticoagulation TMS Programs](#)

3 Prior Authorization Categories on the VANF

If any questions about Prior Authorization, please send email to VHAPBH.Prior.Authorization.National.

The recent issue of Ez Minutes can be read from your smart phone! Put the below link in your browser; hit search... and the current issue from the PBM INTERnet site will be ready to read. <http://www.pbm.va.gov/PBM/ezminutes/current/currentEzMinutes.pdf>

Don't forget...you can also subscribe to Ez-Minutes and any documents posted to the What's New Section on the PBM INTERnet web site by subscribing to the RSS Feed. <http://www.pbm.va.gov/PBM/rss/WhatsNewAtPBMRSSFeed.xml>

Apply Now for **Professionals Accelerating Clinical and Educational Redesign (PACER)**. Applicants are being accepted from Interprofessional teams for a three year program to prepare trainees to work together in high performing patient-centered medical homes. Additional information about how to apply to the program can [be found here](#).



Posting of VAMedSAFE Documents MAY-JULY 2015

- [Ketorolac Recall Due to Particles in Glass Vial: Addendum](#) [July 2, 2015]
- [Nexium Recall Due to Bottle Containing Seroquel Instead](#) [June 24, 2015]
- [SGLT2 Inhibitors and Potential Risk for Acidosis](#) [May 22, 2015]
- [Ferumoxytol and Risk of Serious Allergic Reactions](#) [April 28, 2015]

VHA Oncology Guidance Documents

The VHA Oncology Guidance Document on Determining Clinical Benefit of High Cost Oncology Drugs was initially drafted by the High Cost Oncology Drug Workgroup, a collaboration of VA oncology providers and pharmacists. The purpose of the document is to guide members of the oncology health care team through a decision tree to help optimize patient outcomes while attempting to obtain the greatest value from innovator therapies. Within this document, the process of identifying the clinical benefit had been defined as obtaining improvement in any of the following outcomes: overall survival, progression-free survival, patient-related outcomes, and patient-related goals. As many drugs receive expedited FDA-approval, these outcomes are often times not reached due to the shortened nature of the review process. Attempts to assign a net clinical benefit to these expedited drugs could miscommunicate their value to the field. To address this issue, the guidance document has been updated to address those drugs approved through an expedited process. In addition, the definition of “high cost drugs” has been updated to reflect recent literature. Go to the PBM website to review all the oncology documents! See the link below.

<https://vaww.cmopnational.va.gov/cmop/PBM/Clinical%20Guidance/Forms/AllItems.aspx?RootFolder=%2Fcmop%2FPBM%2FClinical%20Guidance%2FOncology%20Guidance%20Documents&FolderCTID=0x0120006BA3B2280F536A41A2C5A1B0F4AFC943&View={43999405-C9A2-47A4-AE17-15518717FA3E}>

National Contract Awards for Calendar Year 2015

Click on [this link](#) to view the National Contract Awards CY 2015. [InTRAnet only]

Pharmacy-Prosthetics-Logistics (PPL)* Workgroup

The table below depicts the various products reviewed during ^{Feb. 2015} meeting. The X marks which service(s) is responsible for managing the respective products. Please click [HERE](#) for previous recommendations and minutes made from earlier meetings.

*The PPL workgroup was created to help clarify the responsibility for management (e.g., ordering, storing, purchasing, and/or dispensing) of those products in which it is not clear which service should provide. The workgroup is not responsible for determining formulary status, clinical merit, or appropriate use of the products reviewed.

Products	Pharmacy+	Prosthetics+	Logistics+
Actigraphy watches (assist in determining sleep patterns and circadian rhythms)			X
Antibiotic containing resorbable envelope used to stabilize cardiac device placement			X
Dental drills or kits used for dental implants			X
Donor bags for therapeutic phlebotomies			X
Esophageal or tracheal flange (replacement part for voice prosthesis)		X	
Eye drop assistive devices		X	
Histatrol (positive histamine control)	X		
Nebulizers		X (outpatients)	X (inpatients)
Neuro Stim system or military field stimulator (placed in clinic by provider)			X
Punctal plugs		X (permanent)	X (dissolvable)
Replacement dental implants		X	
Scrotal suspensory after surgery			X
Topical aerosol refrigerants			X (inpatient and clinic use)
Tracheoesophageal puncture dilator for outpatients		X	

+Contingent upon approval from VISN or local Clinical Products Review Committee (CPRC). Implementation of these recommendations should be coordinated between services at local sites to ensure a smooth transition if recommendations lead to a change in responsible service. If you have any questions related to this announcement, please contact the responsible local service (Pharmacy, Prosthetics, or Logistics) for more detailed information.



All PBM-MAP-VPE webinars are conducted using the same Adobe Connect meeting link and VANTs number.
<http://va-eerc-ees.adobeconnect.com/pbm-monthly-webinars/>

VANTS: 1-800-767-1750 Access Code 49792#

NEW! Next PBM-MAP-VPE Webinar: August 18th, 2015 @ 3 PM ET

Transforming Clinical Pharmacy Practice:

Key Highlights from VHA Handbook 1108.11 Clinical Pharmacy Services

Links to VHA Handbook 1108.11 <http://vawww.va.gov/vhapublications/> or <http://www.va.gov/vhapublications/>

No Accreditation. Come prepared with your questions!

Any questions, please contact Eric.Esplin@va.gov (EES) or Janet.Dailey@va.gov (PBM)

SAVE-THE DATE: September 15th @ 3 PM ET



HEY PACT TEAMS and ALL PROVIDERS

Have you missed any of the VA-DoD Lipid Guidelines Webinars? Are you new to the VA and need to learn about the VA-DoD Lipid Guidelines? Do you need to learn how to utilize the VA-DoD Lipid Guidelines and apply them to your practice?

The PBM-MAP-VPE and the Employee Education System are pleased to bring the Lipid guideline webinar in September to a computer close to you:

“VA/DoD Dyslipidemia Guidelines for Cardiovascular Risk Reduction and Differences from the ACC/AHA Guidelines”

Objectives:

1. describe how the VA/DoD Guideline differs from the ACC/AHA 2013 Guideline;
2. list at least 2 key aspects of the VA/DoD Guideline; and
3. discuss the implications of the recently published IMPROVE-IT Trial

Accreditation: ACPE, ACCME, ACCME-NP

<http://va-eerc-ees.adobeconnect.com/pbm-monthly-webinars/>

VANTS: 1-800-767-1750 Access Code 49792#

2015 Anticoagulation Revised TMS Programs are Available!

Basic Anticoagulation Program

https://www.tms.va.gov/learning/user/deeplink_redirect.jsp?linkId=ITEM_DETAILS&componentID=6720&componentTypeID=VA&revisionDate=1279916700000

Accreditation: ACPE-T, ANCC, CDR, CA BRN for 3 years

Advanced Anticoagulation Program

https://www.tms.va.gov/learning/user/deeplink_redirect.jsp?linkId=ITEM_DETAILS&componentID=6719&componentTypeID=VA&revisionDate=1279909920000

Accreditation: ACPE, ACCME, ACCME-NP for 3 years

Don't Be Fooled...It's not April 1st... The revision field inside TMS for both programs will depict 2010.....BUT the programs are the new and revised programs. (the field line can not be edited) PBM is developing a 3 part webinar series on anticoagulation related topics later this year. Be sure to complete the Advanced Program in preparation. More details will be forthcoming.

Advanced Anticoagulation Webcourse

Item Summary

Department of Veterans Affairs
6719

Revision:

2 - 7/23/2010 01:32 PM America/Chicago

Description:

The purpose of this knowledge based program is to provide education to all staff who may be involved in caring for patients receiving anticoagulant therapy and to enhance patient safety by familiarizing them to the risks and benefits associated with anticoagulation therapy